Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Recap by typeshit. Full story at ad-hoc-news.de.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
The Partnership for Safe Medicines calls the compounding illegal and risky, as RFK Jr. pitches a state-regulated marketplace for peptides like BPC-157, per RAPS.
Bikman cites a trial where people who lost about 21% and switched to placebo regained 14% within a year, while those who stayed on kept losing.
29:58
Meg takes her weekly tirzepatide shot on camera and steps on the scale to share where her weight loss stands so far.
Loading…